Polyunsaturated fatty acids (PUFAs) affect cardiac excitability. Kv7.1 and the β-subunit KCNE1 form the cardiac IKs channel that is central for cardiac repolarization. In this study, we explore the prospects of PUFAs as IKs channel modulators. We report that PUFAs open Kv7.1 via an electrostatic mechanism. Both the polyunsaturated acyl tail and the negatively charged carboxyl head group are required for PUFAs to open Kv7.1. We further show that KCNE1 co-expression abolishes the PUFA effect on Kv7.1 by promoting PUFA protonation.
Introduction
The cardiac action potential is initiated and maintained by inward sodium and calcium currents and terminated by outward potassium currents (1) . The IKs channel, formed by four α subunits (Kv7.1, originally called KCNQ1 or KvLQT1) and two to four auxiliary β subunits (KCNE1, originally called minK) (1, 2) , contributes a major component of the repolarizing potassium current. More than 300 mutations in the genes encoding Kv7.1 and KCNE1 have been identified in patients with cardiac arrhythmia (1) . Loss-of-function mutations of the IKs channel prolong the QT interval as observed in Long QT syndrome, leading to ventricular arrhythmias, ventricular fibrillation, and sudden death (1) . Gain-of-function mutations of the IKs channel shorten the QT interval, possibly leading to arrhythmia such as Short QT syndrome or atrial fibrillation (1) . Pharmacological augmentation (in the case of Long QT syndrome) or inhibition (in the case of Short QT syndrome) of IKs channel activity is a logical pharmacological strategy to treat these forms of cardiac arrhythmias.
Kv7.1 is a tetrameric voltage-gated K (Kv) channel with six transmembrane segments (called S1-S6) per subunit (3) . S5 and S6 from all four subunits together form the pore domain with the central ion-conducting pore. S6 has been shown to function as the activation gate, shutting off the intracellular access to the pore for K + ions in the closed state of the channel (3) (4) (5) .
Most reported activators or inhibitors of Kv7.1 channels target the ion-conducting pore domain of the channel, opening or blocking the ionic pathway (6) (7) (8) (9) (10) . S1 to S4 of each subunit form a voltage-sensor domain (VSD). Each S4 segment has several positivelycharged residues and has been shown to move in response to changes in the transmembrane voltage (3, 11) . In response to membrane depolarization, the S4 segments move outward with respect to the membrane, which causes channel opening. Although four Kv7.1 subunits per se form a functional channel, Kv7.1 needs to co-assemble with the auxiliary β-subunit KCNE1
to recapitulate the biophysical properties of the native cardiac IKs channel (12, 13) . KCNE1, a single transmembrane helix protein, has been proposed to associate with Kv7.1 in the lipid cleft between adjacent VSDs, making contact with VSD transmembrane segments S1 and S4
and pore transmembrane segment S6 (14) (15) (16) .
In this study, we explore the prospects of polyunsaturated fatty acids (PUFAs) and PUFA analogues as small molecules enhancing or inhibiting the activity of the cardiac IKs channel by changing IKs channel voltage dependence. The pharmacological sensitivity of IKs to smallmolecule activators has been shown to depend on the Kv7.1:KCNE1 stoichiometry (17-19).
We therefore also determine the impact of Kv7.1:KCNE1 stoichiometry on PUFA sensitivity.
Below we show that PUFAs affect the Kv7.1 channel by an electrostatic effect on the voltage sensor movement. We also show that KCNE1 abolishes the PUFA sensitivity of the Kv7.1 channel at physiological pH, suggesting that physiologically occurring PUFAs do not act on IKs channels in vivo. Furthermore, we identify new PUFA analogues that have effects on the IKs channel at physiological pH, increase IKs in cardiomyocytes, restore rhythmic firing in arrhythmic cardiomyocytes, and shorten the QT interval in isolated perfused guinea pig hearts. These results may form the basis for development of pharmacological drugs that target the IKs channel to prevent cardiac arrhythmias.
Results

n-3 PUFAs open Kv7.1 channels via an electrostatic mechanism
Extracellular application of the n-3 (or -3) PUFA docosahexaenoic acid (DHA) (in the concentration range of total circulating plasma PUFAs (20-22)) activates Kv7.1 channels by shifting the conductance versus voltage (G(V)) curve of human Kv7.1 in negative direction along the voltage axis ( Fig. 1A-B ) and changing Kv7.1 channel kinetics ( Fig. S1A-B) . 70 µM DHA shifts the G(V) by 9.3 ± 0.9 mV (n = 3). 7 M DHA induces significant G(V) shifts (3.0 ± 0.5 mV (n = 3, P < 0.05). The estimated maximum shift is 15.8 ± 2.3 mV (from Eq.
3) and 50% of the maximum shift is caused by 50 ± 20 M DHA (Fig. 1C) .
To determine the molecular mechanism of how DHA facilitates Kv7.1 channel opening, we explore the structural requirements of the DHA molecule to facilitate channel opening. We test the importance of the DHA head charge (1-3 below) and the DHA acyl tail (4 below) in four sets of experiments:
1) We test the effect of the uncharged PUFA analogue DHA methyl ester (70 M) and find that it does not change the voltage dependence of Kv7.1 ( Fig. 2A , Table S1 ). In contrast, the positively charged arachidonyl amine (AA+, 70 M) and the positively charged docosahexaenyl amine (DHA+, 70 M) shift the G(V) curve by +9.7 ± 2.1 mV (n = 8) and +7.8 ± 3.0 mV (n = 10), respectively ( Fig. 2A) . These data suggest that a charged PUFA head group is required for shifting the G(V) curve of the Kv7.1 channel. The valence of that charge determines the direction of the G(V) shift, as if the PUFA -Kv7.1 channel interaction is electrostatic.
2) We test the effect of pH on the G(V) shifts induced by PUFAs. Unsaturated fatty acids in a lipid environment are protonated/deprotonated with an apparent pKa ≈ 7 (23, 24) (illustrated in Fig. S1C ). The apparent pKa value for DHA on Kv7.1 is ≈ 7.7 as reported by the shift of the G(V) relation (Fig. 2B) . Increasing external pH from 7.4 to 9 or 10 increases the shift in negative direction of the G(V) curve protocol by DHA, whereas reducing external pH to 6.5 abolishes the DHA effect (Fig. 2C) .
3) We co-apply 70 µM DHA and 70 µM DHA methyl ester and find that DHA methyl ester reduces the shift of the G(V) relation (5.5 ± 0.6 mV, n = 4) compared to application of 70 µM DHA alone (9.3 ± 0.9 mV) ( Fig. S2A-B) . The induced G(V) shift from co-application of 70 µM DHA and 70 µM DHA methyl ester (5.5 mV) is close to that produced by 35 µM DHA alone (6.5 mV) (Fig. S2C) , as if the uncharged DHA methyl ester competes with DHA for binding but has by itself no effect on Kv7.1 channel activation.
4)
We test the effects of another PUFA with a slightly shorter tail (eicosapentaenoic acid, EPA) and of the monounsaturated oleic acid ( Fig. 2A) . The length of the acyl chains of EPA and oleic acid differ by only two carbons. The main difference between EPA and oleic acid is the number of double bonds in the acyl chain where EPA contains five double bonds and oleic acid only one double bond. The polyunsaturated EPA is similar in its effect on Kv7.1 as DHA, whereas the monounsaturated oleic acid has no effect ( Fig. 2A and Table S1 ). This suggests that a polyunsaturated acyl tail is required for shifting the Kv7.1 channel voltage dependence.
In summary, both a negatively charged head group and a polyunsaturated acyl tail of the PUFA are required for shifting the G(V) curve of the Kv7.1 channel in the negative direction along the voltage axis. These structural requirements of the PUFA molecule to modulate Kv7.1 channel activity are similar to the structural requirements of PUFAs for modulating the Shaker Kv channel (23, 25, 26) . In analogy with the mechanism for PUFA suggested for the Shaker Kv channel (23, 27), we hypothesize that the negatively-charged head group of PUFA interacts electrostatically with the VSD of Kv7.1 in facilitating channel opening and that the polyunsaturated acyl tail of PUFA is important to locate the PUFA molecule to the otherwise phospholipid filled space between two neighboring VSDs (illustrated in Fig. 2D ). prevents 70 M DHA from shifting the G(V) of Kv7.1 ( Fig. 3A-B ; Table S1 ).
We test in the following three possible explanations of why KCNE1 reduces the DHA efficacy on Kv7.1 channels: (1) DHA binds to the Kv7.1/KCNE1 channel, but its effects are masked by the strong KCNE1 effects on Kv7.1 activation gating. (2) KCNE1 excludes DHA from binding to a shared location on Kv7.1. (3) KCNE1 modifies the local environment of the head group of the PUFAs, thereby reducing DHA potency (for instance, by altering the local proton concentration). We use different Kv7.1 and KCNE1 constructs to distinguish among these possible explanations.
1) KCNE1-induced reduction of DHA sensitivity is not due to altered activation gating
We co-express Kv7.1 with a KCNE1 construct in which the C-terminus is truncated (KCNE1ΔC). This construct was previously shown to associate with Kv7.1 (28) but to alter channel kinetics and voltage dependence only to a small degree: Kv7.1/KCNE1ΔC kinetics and activation voltage dependence are similar to these of Kv7.1 alone (Fig. S3A) . The Kv7.1/KCNE1ΔC channel is however insensitive to 70 µM DHA (Fig. S3A, relation by a small positive voltage ( Fig. S3B-C) . This positive shift (observed at external pH 7.4) is unique for the concatemeric channels, because it is not seen in WT Kv7.1/KCNE1 channels ( Table S1 ). This positive shift does not require the negative charge of the DHA head group because the uncharged DHA methyl ester induces a similar positive shift in both concatemeric channels (Table S1 ). Experiments on these concatemeric channels show that a Kv7.1 channel with only two KCNE1 subunits is also not sensitive to DHA.
3) KCNE1-induced reduction of DHA sensitivity is due to protonation of DHA Table S1 ). These shifts are comparable to the DHA-induced G(V) shift of Kv7.1 alone at pH 9 ( Table S1 ). These data suggests that DHA binds to Kv7.1 channels co-expressed with KCNE1, and that KCNE1 lower the local pH close to the head group of the PUFAs. KCNE1
3C-E,
alters the apparent pKa value for DHA from 7.7 to 8.6 (Fig. 3E) 
PUFA analogues effective on Kv7.1/KCNE1
If KCNE1 decreases the G(V) shifting potency of DHA by lowering the local pH close to the head group of the PUFAs and thereby neutralizing acidic PUFAs by protonation (illustrated in Fig. 3F upper panel) , then we expect KCNE1-induced protonation to increase the effect of amino-analogues of PUFAs (illustrated in Fig. 3F lower panel) . This expectation is met by experimental data; 70 µM arachidonyl amine at pH 7.4 shifts the G(V) curve of the Kv7.1/KCNE1 channel by +22.6 ± 1.9 mV (n = 10) (Fig. 3G, Table S1 , Fig. S4A ), compared to only +9.7 ± 2.1 mV (n = 8) for Kv7.1 alone (Fig. 3G , Table S1 ). In addition, DHA and arachidonyl amine have opposite pH dependence of their effect on Kv7.1/KCNE1: the G(V)
shifting potency of DHA increases with increasing pH, while the potency of arachidonoyl amine decreases with increasing pH (Fig. S5A) .
To further test if KCNE1 reduces the effect of PUFAs on the Kv7.1 channel via a local pH reduction, we use the PUFA analogue docosahexaenoyl glycine (DHA-Gly), whose lower pKa value should keep the DHA-Gly molecule deprotonated at physiological pH. 70 µM DHA-Gly shifts by a similar amount the G(V) curves of channels formed by Kv7.1 alone and by Kv7.1 together with KCNE1 (25 mV; Fig. 4A, Fig. S4B , Table S1 ). DHA-Gly has an apparent pKa-value of 7.1 for Kv7.1/KCNE1, which is about 1.5 pH unit lower than that of DHA ( Fig. 4B) . Moreover, a permanently-charged PUFA analogue, which is not protonated or deprotonated by changes in the local pH in our experimental setting, should be equally effective on Kv7.1 alone as on Kv7.1/KCNE1. 70 µM of the permanently negatively charged N-arachidonoyl taurine shifts by a similar amount the G(V) curves of Kv7.1 channels with and without KCNE1 (26 to 27 mV; Table S1 , Fig. 4C, Fig. S4C ). N-arachidonoyl taurine also increases the maximum conductance of Kv7.1/KCNE1 (Fig. S4C) . The mechanism for this is unclear.
These results show that even in the presence of KCNE1, Kv7.1 is activated by a PUFA analogue with a lower pKa value and a PUFA analogue with a permanent negative charge, supporting the hypothesis that KCNE1 reduces the local pH and thereby modifies the sensitivity to PUFAs. A simple model can recapitulate the pH dependence of DHA and DHAGly on Kv7.1 and Kv7.1/KCNE1 ( Fig. S5B-C) . Furthermore, we also note that the G(V)
shifts of (i) Kv7.1 induced by 70 μM DHA at pH 9 and 10 (almost fully deprotonated), of (ii)
Kv7.1/KCNE1 by 70 μM DHA at pH 9 (almost fully deprotonated), of (iii) Kv7.1 and Kv7.1/KCNE1 by 70 μM DHA-Gly at pH 7.4 (almost fully deprotonated), and of (iv) Kv7.1 and Kv7.1/KCNE1 by 70 μM N-arachidonoyl taurine at pH 7.4 (negatively charged) are all about 30 mV, suggesting that, as long as the PUFA is charged, the effect of the PUFA is independent of KCNE1.
PUFAs target the VSD
Because PUFAs require a charged head group to affect Kv7.1 channel activity, we hypothesize that the PUFAs electrostatically facilitate Kv7. . In addition to S4 gating charge residues, also other residues in the top of S3 and S4 were previously shown to be important for the PUFA effect on the Shaker channel (26). We therefore also test the effect of K218C and G219C, located in the S3-S4 loop of Kv7.1, on PUFA potency. Both these mutations reduce the effect of 70 µM DHA-Gly on Kv7.1 ( Fig. 4D ) and reduce the affinity of DHA-Gly by a factor of ~3-4 ( 
PUFA analogue restores cardiac rhythm
We test the effect of N-arachidonoyl taurine on isolated embryonic rat cardiomyocytes gestation day 16, in which there is IKs expression but no IKr expression (34) . 30 µM Narachidonoyl taurine shortens the cardiomyocyte action potential duration (APD50) by 17 ± 3% (n = 5, P < 0.05) and increases the frequency of action potential firing by 26 ± 5% (n = 5, P < 0.05) (Fig. 5A-B , Table S2 ). 30 µM N-arachidonoyl taurine has no effect on the resting membrane potential compared to control (Table S2) , but decreases the action potential peak amplitude by 9 ± 1 mV (Table S2) Chromanol 293B blocks this current by 91 ± 5% (n = 3) at +10 mV, suggesting that the main part of this current is IKs. Application of 30 µM N-arachidonoyl taurine increases this current by 103 ± 68% at +10 mV (n = 5, P = 0.005) (Fig. 5C, Figure S7A ). To induce arrhythmia in the embryonic rat cardiomyocytes, we apply a sub-saturating concentration of Chromanol 293B, which is known to prolong the cardiac action potential duration and induce arrhythmia (35) . 5 µM Chromanol 293B increases the action potential duration (APD50) by 30 ± 11% (n = 6, P < 0.05) (Fig. S7B) . With time, two types of effects (sometimes within the same cell)
are seen upon 5 µM Chromanol 293B application:
(1) In 4 out of 10 cells we see arrhythmic firing with pronounced variation in the frequency of action potential firing ( Fig. 5D-E, Fig. S7C ). During this arrhythmic firing, there is a large variation in action potential duration (Fig. S7D) due to double peaks and irregular RRinterval.
(2) in 9 out of 10 cells we see a slowing of the frequency of spontaneous action potential firing ( Fig. S7E-F) . The mean increase in RR-interval is 387 ± 95% (n = 9, P < 0.05). The slowing in action potential firing induced by Chromanol 293B is in line with earlier studies of Long QT mutations in Kv7.1 channels in patients for whom bradycardia has been reported (36, 37) . The mechanism of how Long QT mutations in Kv7.1 could cause bradycardia is not clear.
These two different effects of Chromanol 293B are most likely due to different subtypes of cardiomyocytes. Independent of the type of effect induced by Chromanol 293B application, 30 µM N-arachidonoyl taurine reverses the effect: abolishing the arrhythmic firing (Fig. 5F,   Fig. S7C ) or restoring the frequency of spontaneous action potential firing (Fig. S7G , the RRinterval in co-application of Chromanol 293B and N-arachidonoyl taurine is not significantly different to control (P > 0.05)).
PUFA analogue restores QT interval
To test the effect of a PUFA analogue on an intact heart, we apply DHA-Gly on isolated perfused guinea pig hearts. To mimic a Long QT setting, first, 0.03 µM of the IKr blocker E4031 is perfused into the guinea pig heart to prolong the QT interval and action potential duration ( Fig. 5G-I ). 20 minutes perfusion of 0.03 µM E4031 increases the QT interval by 23.6 ± 3.6 ms (n = 3, P < 0.05) and prolongs the action potential duration (APD90) by 14.3 ± 2.2 ms (n = 3, P < 0.05). Perfusion of the guinea pig heart with 0.03 µM E4031 together with 10 µM DHA-Gly reverses the E4031-induced QT prolongation and E4031-induced prolongation of action potential duration ( Fig. 5G-I) . Perfusion with 0.03 µM E4031 or 10 µM DHA-Gly produces no significant effects on intrinsic heart rate ( Fig. S7H ).
Discussion
In this study, we show that small-molecules (PUFAs and PUFA analogues) activate or inhibit the Kv7.1 channel. We describe a novel mechanism by which the auxiliary KCNE1 subunit alters the pharmacological sensitivity of the Kv7.1 channel. KCNE1 reduces the Kv7.1 channel sensitivity to regular PUFAs by promoting PUFA protonation. In contrast, KCNE1
increases the Kv7.1 channel sensitivity to the positively charged PUFA analogue arachidonyl amine by promoting amine protonation. The effect on Kv7.1 of the PUFA analogues docosahexaenoyl glycine, which has a lower pKa value, and of N-arachidonoyl taurine, which is permanently charged, are not modified by KCNE1 co-expression. Thus, understanding the mechanism for how KCNE1 tunes the pharmacological sensitivity of Kv7.1 allows us to chemically by-pass the auxiliary subunit interference of KCNE1.
The similarity in PUFA modulation of Kv7.1 (reported here) and the Shaker Kv channel (23, 
Materials and Methods
Molecular biology
Expression plasmids human KV7.1 (GenBank Acc. No. NM_000218) in pXOOM and KCNE1 (NM_000219) in pGEM have been previously described (49, 50). The truncation construct KCNE1ΔC was generated by introducing a Stop codon at position 67 using mutated oligo extension PCR. The concatemers E1-KV7.1-KV7.1 and E1-KV7.1 were kindly provided by Dr. R.S. Kass at Columbia University, NY, USA, and contained mutations to make the constructs suitable for voltage-clamp fluorometry recordings (51). Mutated cDNA was replaced by wild-type subunits by standard cloning techniques. All newly generated constructs were sequenced to ensure integrity (Genewiz, NJ, USA). cRNA was prepared from linearized DNA using the T7 mMessage mMachine transcription kit (Ambion, TX, USA).
RNA quality was checked by gel electrophoresis, and RNA concentrations were quantified by UV spectroscopy.
Experiments on Xenopus laevis oocytes
Xenopus laevis oocytes were isolated and maintained as previously described (9) .
Approximately 50 nl cRNA (50 ng Kv7.1, KCNE1-Kv7. 
Experiments on rat cardiomyocytes
On gestation day 16 of pregnancy, time-mated Sprague Dawley rats (Taconic, Denmark) were anesthetized in a CO2 chamber followed by cervical dislocation. Cell preparation of cardiomyocytes and culturing on glass coverslips were made as previously described (34) .
Animal experiments were approved by the local ethics committees. Spontaneous action potentials and currents were measured using the patch-clamp technique in whole cell 
Isolated, perfused heart preparations
Female guinea-pigs (Dunkin Hartley, 450-600 g, Charles River, France) were anaesthetized with sodium pentobarbitale supplemented with lidocainhydrochloride (Sygehus Apotekerne, Denmark). Upon thoracotomy, the aorta was cannulated to start a retrograde coronary perfusion with a modified Krebs'-Henseleit solution that contained in mM: NaCl 120.0; KCl 4.0; NaHCO3 25.0; glucose 11.0; MgSO4 0.6; KH2PO4 0.6, and CaCl2 2.5.The solution was gassed with 95% O2, 5% CO2 and warmed (37°C), to maintain pH at 7.4. Finally, the excised heart was mounted on a Langendorff-perfusion apparatus (Hugo Sachs-Harvard Apparatus GmbH, Germany) and perfused at a constant pressure of 60 mmHg. ECG signals were recorded using 3 ECG electrodes. A monophasic action potential electrode was placed on the right ventricle and a pacing electrode on the right atrium. Pacing periods consisted of 2 min pacing at 250 beats per minute (BPM). All data were acquired at 2 kHz using a 16-channel PowerLab system (ADInstruments, UK). The heart stabilized for minimum 30 minutes followed by 2 minutes of pacing in order to record baseline EGC and APD90 at a constant heart rate. Next, the hERG/Kv11.1 inhibitor E4031 (0.03 µM) was added to the perfusate for 20 min and data was acquired during 2 min atrial pacing. Finally 10 µM DHA-Gly was added to the perfusate and the heart was paced for 2 min every 10th minute. All data are presented as the mean of the last 1 min recording during pacing. Drug effects on intrinsic heart rate were evaluated before initiation of pacing. 4, 7, 10, 13, 16 ,19-all-cis-docosahexaenoic acid (DHA), 4,7,10,13,16,19-all-cisdocosahexaenoic acid methyl ester (DHA-me), 5,8,11,14,17-all-cis-eicosapentaenoic acid (EPA), and methyl 9-cis-octadecenoic acid (oleic acid) were purchased from Sigma-Aldrich.
Test compounds
Docosahexaenoyl glycine and N-arachidonoyl taurine were purchased from Cayman Chemical. N-arachidonoyl taurine is a very strong acid and is expected to be always ionized when in solution. It is therefore referred to as permanently charged. Synthesis of arachidonyl amine and docosahexaenoyl amine were performed as described in Supplementary Figure   S8 . Test compounds were dissolved in 99.5% ethanol to a concentration of 100 mM and diluted shortly before experiments as previously described (23, 25) . We expect all test compound concentrations of 70 µM and lower to be below the critical micellar concentration in our experimental setting (23, 52). For the highest DHA concentration used, 210 µM, we cannot be sure that there is no micelle formation. If we have micelle formation at 210 µM DHA, the free DHA concentration will not be 210 µM which may affect our concentrationresponse estimates in Fig. 1C and Fig. 2C and tend to overestimate the c0.5. The estimates for c0.5 should therefore be seen as an approximation. Control solution was added to the bath using a gravity-driven perfusion system. To avoid binding of test compounds to the perfusion system, test solutions were added manually with a glass Pasteur pipette. Previously, the effective concentration of fatty acids was determined to be 70% of the nominal concentration due to binding to the Perspex chamber (23). All fatty acid and fatty acid analogue concentrations denoted are the estimated effective concentrations, i.e. 70% of the nominal concentration. Generally, the test compound effect was poorly reversible. The PUFA effect could not be washed away with pure control solution. When adding 100 mg/L albumin during washing the recovery was much improved however not complete.
To avoid possible cyclooxygenase enzyme metabolization of arachidonyl amine and Narachidonoyl taurine, oocytes were pretreated with 1 µM indomethacin, and 1 µM indomethacin was supplemented to the recording solutions as previously described (23).
Electrophysiological analysis
To quantify effects on the voltage dependence, tail currents (measured shortly after initiation of repolarization) were plotted against the prepulse (test) voltage. The following Boltzmann relation was fitted to the control curve and the given slope factor was noted
where V½ is the midpoint and s the slope factor. The same To quantify the concentration dependence and pH dependence of the DHA-induced shift of voltage dependence, ΔV, the following equation was used:
where ΔVmax is the maximal shift, c0.5 the concentration causing 50% of the maximal shift, and c the concentration of DHA (or H + ). 
Statistical analysis
